Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Immune checkpoint inhibitors can increase the risk of autoimmune skin diseases, especially bullous pemphigoid.

Standard dosing is more effective for severe alopecia areata in children, but unorthodox dosing can be safe and considered if needed.

Cell-mediated drug delivery systems improve skin disease treatment by using living cells for precise, prolonged, and less toxic therapy.

These new skin treatments are safer and more effective with minimal side effects.

Follicular dystrophy in immunocompromised patients may be linked to medication or viral factors and can improve with treatment changes.

Tacrolimus ointment is effective for various skin conditions but needs more research for long-term effects.

Azathioprine is the most continued treatment for chronic alopecia areata over a year, often with added low-dose prednisolone.

New targeted therapies for psoriasis show promise but face challenges like side effects and treatment resistance.

Blocking androgen receptors helps immune cells better fight certain bacteria.

CS12192 effectively treats alopecia areata with better safety than current options.

A woman on immunosuppressants developed two rare scalp conditions, which improved with specific treatments.

Bimekizumab quickly improves psoriasis symptoms and skin at the molecular level.

IL-17 and IL-23 inhibitors can cause skin reactions that may require different treatments.

Increasing Treg cells in the skin does not cure hair loss from alopecia areata in mice.

miR-486 may help prevent hair loss in alopecia areata.

Using polymeric micelles to deliver spironolactone topically could improve wound healing in skin affected by glucocorticoids.

Amotosalen-treated donor T-cells can prevent late CMV infection after bone marrow transplants.

JAK inhibitors can be safely used for alopecia areata in patients with latent hepatitis B or stable tuberculosis with proper monitoring.

The combination therapy improved severe alopecia areata in a patient after 14 days.

Tridax procumbens may boost the immune system.

Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.

Mogamulizumab treatment in Sézary syndrome may cause skin issues and hair loss but can lead to a complete response.

JAK inhibitors show promise for treating skin disorders like alopecia, eczema, and psoriasis.

TLR7-based compounds may help manage chemotherapy-induced hair loss.

Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.

The microneedle patches effectively treat allergic conjunctivitis with controlled, sustained release of medication.

JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.

Antioxidant nanoparticles show promise for treating inflammatory diseases but need more research for safe and effective use.

New acne treatments like clascoterone and minocycline foam are effective, and using antibiotics carefully is important to avoid resistance.